OTC silde­nafil phar­macy fail

Pharmacy Daily - - Front Page -

AU­THOR­I­TIES in New Zealand have high­lighted a high pro­por­tion of phar­ma­cists in­ap­pro­pri­ately sup­ply­ing erec­tile dys­func­tion med­i­ca­tion silde­nafil.

A Phar­macy Qual­ity Au­dit Up­date is­sued by the coun­try’s Med­safe reg­u­la­tor re­lates to au­dits un­der­taken in the first quar­ter of 2018, which have been in­tro­duced un­der a new risk-based frame­work cur­rently be­ing phased in.

The doc­u­ment cites ex­am­ples of silde­nafil sup­plied out­side of guide­lines, such as to pa­tients with high blood pres­sure or other car­dio­vas­cu­lar is­sues.

Some sup­plies were in quan­ti­ties greater than the al­lowed max­i­mum of 12 tablets, or in bro­ken packs, and phar­ma­cies were not al­ways able to demon­strate that there was a sys­tem in place for record­ing con­sul­ta­tions re­lated to the re­sup­ply of the med­i­ca­tion.

The is­sues were high­lighted un­der a spe­cific qual­ity cri­te­rion which stated that medicines re­quir­ing sup­ply by an ac­cred­ited phar­ma­cists should be “recorded, sold and la­belled in ac­cor­dance with reg­u­la­tory and pro­fes­sional re­quire­ments”.

Of more than 70 phar­ma­cies au­dited dur­ing the pe­riod, on ei­ther a pre-no­ti­fied or unan­nounced ba­sis, just 17% were found to have at­tained the re­quired stan­dard.

Al­most a third of the phar­ma­cies (29%) were clas­si­fied as hav­ing “high” or “crit­i­cal” risk lev­els in this area, with Med­safe say­ing the sig­nif­i­cant level of non-com­pli­ance was con­cern­ing.

“The phar­macy sec­tor is en­cour­aged to work to­wards sig­nif­i­cant im­prove­ment in this area, par­tic­u­larly in the sup­ply of silde­nafil,” the reg­u­la­tor ad­vised.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.